C07K2319/04

ENGINEERED AND FULLY-FUNCTIONAL CUSTOMIZED GLYCOPROTEINS
20210332403 · 2021-10-28 ·

Described herein are compositions and methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.

Fusion protein for improving protein expression from target mRNA

[Problem to be Solved] The object of the present invention is to develop a method of regulating a target RNA. [Solution] There is provided a fusion protein comprising a functional domain which improves the protein expression level from mRNA and a PPR protein which can bind to a target mRNA in an RNA base-selective or RNA base sequence-specific manner.

MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES
20210253648 · 2021-08-19 ·

The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin-derived polypeptides which comprise embedded T-cell epitopes and are de-immunized. The present invention provides cell-targeted, CD8+ T-cell epitope delivering molecules for the targeted delivery of cytotoxicity to certain cells, e.g., infected or malignant cells, for the targeted killing of specific cell types, and the treatment of a variety of diseases, disorders, and conditions, including cancers, immune disorders, and microbial infections. The present invention also provides methods of generating polypeptides capable of delivering one or more heterologous T-cell epitopes to the MHC class I presentation pathway, including polypeptides which are 1) B-cell and/or CD4+ T-cell de-immunized, 2) comprise embedded T-cell epitopes, and/or 3) comprises toxin effectors which retain toxin functions.

NOVEL CELLULAR RECEPTORS AND USES THEREOF

Described herein are polypeptides, systems, and methods that relate to using domains that bind specifically to a biotinylamide to control receptor and cellular activity.

Production of highly thermally stable recombinant cholinesterases for the detection, detoxification and decontamination of organophosphorus compounds
11008554 · 2021-05-18 · ·

Disclosed herein are methods for the large-scale production of a highly thermally stable acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Additionally, the expression methods disclosed herein can produce ChE preparations consisting of extract or purified forms that can be produced in high amounts and are highly thermally stable. These ChE products can be used in vitro detection, detoxification and decontamination methods.

Recombinant vector for expressing target protein in plant cell
11845945 · 2023-12-19 · ·

Provided is a technique for highly expressing a target protein in a plant cell by using a glycosylation domain, a recombinant vector comprising a gene encoding a fusion protein of a glycosylation domain and a target protein, a recombinant cell, a transformed plant, and a method of producing a target protein using these.

RECOMBINANT FUSION PROTEIN AND IMMUNOGENIC COMPOSITION

A recombinant fusion protein includes a receptor associated protein 1 (RAP1), a cluster of differentiation 28 (CD28)-Pseudomonas exotoxin A translocation domain (PEt) fusion polypeptide, a legumain protein and a target peptide. The RAP1 is located at the N-terminus of the recombinant fusion protein. The CD28-PEt fusion polypeptide is located at the C-terminus of the RAP1. The legumain protein is located at the C-terminus of the CD28-PEt fusion polypeptide. The target peptide is located at the C-terminus of the legumain protein. In another embodiment of the present disclosure, an immunogenic composition is provided. The immunogenic composition including the recombinant fusion protein and an adjuvant is used for inducing specific immune responses in a subject with cancer, whereby the risk of cancer metastasis and recurrence for the subject may be successfully reduced.

MODIFIED NK-92 CELLS FOR TREATING CANCER
20210054337 · 2021-02-25 ·

Provided herein are NK-92 cells expressing at least one CAR and at least one Fe receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient NK-92-Fc-CAR.

VIRAL VECTOR PRODUCTION SYSTEM
20210079360 · 2021-03-18 ·

Disclosed herein are viral vector production systems secreting nuclease for degradation of residual nucleic acid during viral vector production and methods of the same. Such a viral vector production system comprises a viral vector production cell comprising nucleic acid sequences encoding: 1) viral vector components; and 2) a nuclease, wherein the nuclease is expressed in the production cell and secreted in cell culture thereby degrading residual nucleic acid during viral vector production. Another such viral vector production system comprises 1) a viral vector production cell comprising nucleic acid sequences encoding viral vector components; and 2) a nuclease helper cell comprising a nucleic acid sequence encoding a nuclease, wherein the nuclease is expressed and secreted in co-culture of the production cell of 1) and the helper cell of 2), thereby degrading residual nucleic acid during viral vector production.

Recombinant vector carrying cellulose binding domain and method for isolating and purifying protein, using same vector
10934558 · 2021-03-02 · ·

The present invention relates to a recombinant vector carrying cellulose-binding domain 3 and a method for separating a target protein using the recombinant vector. The protein isolating method of the present invention can easily separate a fusion protein containing a target protein by using the recombinant vector to bind a transformed plant body to cellulose and can effectively isolate the target protein from a cellulose-binding domain by treating the fusion protein with enterokinase, thus being expected to find industrial applications in various fields.